PA5-42853

antibody from Invitrogen Antibodies

Targeting: NT5DC2 FLJ12442

Provider product page for PA5-42853

Western blot

Other assay

Antibody data

Antibody Data
Antigen structure
References [1]
Comments [0]
Validations
Other assay [2]

Submit

Product number: PA5-42853 - Provider product page
Provider: Invitrogen Antibodies
Product name: NT5DC2 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Description: Peptide sequence: IRKYDYNPSF AIRGLHYDIQ KSLLMKIDAF HYVQLGTAYR GLQPVPDEEV Sequence homology: Cow: 100%; Dog: 100%; Guinea Pig: 100%; Horse: 100%; Human: 100%; Mouse: 86%; Rabbit: 100%; Rat: 100%; Zebrafish: 79%
Reactivity: Human
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 0.5 mg/mL
Storage: -20° C, Avoid Freeze/Thaw Cycles

NT5DC2 protein structure - PA5-42853 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 3 NT5DC2 interacts with TEAD4 and reduces its ubiquitin-mediated degradation. A and B, Correlation analysis between the expression of NT5DC2 and TEAD4 in 80 LMS cases in TCGA (A) and in combined LMS cases and normal smooth muscle tissues (colon, small intestine and vagina) in GTEx (B). C, Comparison of TEAD4 expression in representative normal smooth muscle tissues, including colon (N = 308), small intestine (N = 92) and vagina (N = 85) from GTEx project and LMS tissues (N = 80). D, K-M survival analysis of PFS in 80 LMS cases in TCGA. Patients were separated into two groups according to the best cut-off of TEAD4 expression. E, Western blot analysis showing the relative TEAD4 expression in ST-LMS-1 and SK-UT-1 cells 48 h after infection of lentivirus carrying NT5DC2 shRNA or scrambled control. F, SK-LMS-1 and SK-UT-1 cells infected with NT5DC2 shRNA or scramble control were treated with MG132 (10 mumol/L, 6 h). The expression levels of TEAD4 and NT5DC2 were assessed by western blot assay. G, Co-IP assays were performed to check the interaction between endogenous NT5DC2 and TEAD4 in SK-LMS-1 (left) and SK-UT-1 (right) cells. IgG was used as a control. H, Cycloheximide pulse-chase assay was performed in SK-LMS-1 cells with mtTEAD4 overexpression alone or in combination with NT5DC2 knockdown or overexpression. 36 h after lentiviral infection, cells were treated with 10 mumol/L CHX for the indicated time, followed by western blot analysis. I, Co-localization of NT5DC2 (red

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 5 TEAD4 inhibition suppresses LMS cell proliferation in vitro and tumour growth in vivo. A and B, RT-qPCR analysis showing the relative TEAD4 expression in ST-LMS-1 (A) and SK-UT-1 (B) cells 48 h after infection of lentivirus carrying TEAD4 shRNA or scrambled control. C and D, Western blot assay of TEAD4 and NT5DC2 expression in ST-LMS-1 and SK-UT-1 cells 48 h after infection of lentivirus carrying TEAD4 shRNA or scrambled control. E and F, The proliferation of SK-LMS-1 (E) and ST-UT-1 (F) cells with or without TEAD4 knockdown. G, Representative images of colony formation (up) and quantitation or relative colony capability (down) of SK-LMS-1 (left) and SK-UT-1 (right) cells with or without TEAD4 knockdown. H and I, SK-LMS-1 cells infected with TEAD4 knockdown (shRNA) or scramble control were subcutaneously implanted into nude mice, and the tumours were harvested 4 weeks later (H). Compared with the controls, TEAD4 knockdown significantly inhibited tumour growth (I). *Comparison with sh NT5DC2 #1, # Comparison with sh NT5DC2 #2, * and # P